# Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

> **NCT04791839** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 30 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Non-small Cell Carcinoma
- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Zimberelimab
- **DRUG:** Domvanalimab
- **DRUG:** Etrumadenant

## Key facts

- **NCT ID:** NCT04791839
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-04
- **Primary completion:** 2026-10-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04791839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04791839, "Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04791839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*